The latest unsurprising development in 23andMe’s story is the admission, by their new board of directors, that 23andMe now does not have enough cash to continue for the next 12 months. They are now ...
The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...
After a market-wide panic over AI start-up DeepSeek, CNBC’s Jim Cramer reflected on what the new player’s entrance into the ...